| Hans-Günter Meyer-Thompson | Naloxon
Promises and perils of the FDA's over-the-counter naloxone reclassification.
Promises and perils of the FDA's over-the-counter naloxone reclassification.
Zhu DT, Tamang S, Humphreys K.
Lancet Reg Health Am. 2023 May 22;23:100518. doi: 10.1016/j.lana.2023.100518. PMID: 37497396; PMCID: PMC10366474.